Increasing Permeability Segment to dominate North America Blood Brain Barrier Technologies Market during 2021–2028
According to The Insight Partners market research study on “North America Blood Brain Barrier Technologies Market to 2028 – COVID-19 Impact and Regional Analysis and Forecast by Technology and Application,” is expected to reach US$ 1,936.23 million by 2028 from US$ 391.56 million in 2021. The market is estimated to grow at a CAGR of 25.7% from 2021 to 2028. The report provides trends prevailing in the North America blood brain barrier technologies market along with the drivers and restraints pertaining to the market growth. Growing geriatric population and rising prevalence of age-associated neurological disorders, raising prevalence of neurological disorders, and vast number of product approvals and launches are the major factor driving the growth of the North America blood brain barrier technologies market. However, issues in brain medication delivery hinders the growth of North America blood brain barrier technologies market.
The worldwide impacts of COVID-19 are being felt across several markets. Although the healthcare sector has witnessed SARS, H1N1, and other outbreaks in the last few years, the severity of the COVID-19 has made the situation more complicated due to its mode of transmission. New research published in December 2020 suggests COVID-19 can cross the blood-brain barrier. The finding gives credence to the many patients who complain of lingering cognitive side effects long after contracting the disease. The University of Washington School of Medicine researchers in Seattle led the study, which looked at how the coronavirus spike protein behaves in mice. This S1 protein, they found, can cross the blood-brain barrier and grab onto other cell receptors, which may be toxic to brain tissue.
The North America blood brain barrier technologies market is segmented on the basis of technology, application, and country. Based on technology, the blood brain barrier technologies market is segmented into bispecific antibody RMT approach, trojan horse approach, increasing permeability, passive diffusion, and other non-invasive BBB technologies. In 2021, increasing permeability segment held the largest share in the market, and it is also expected to be the fastest growing segment during the forecast period. On the basis of application, the blood brain barrier technologies market is segmented into alzheimer’s disease, epilepsy, parkinson’s disease, multiple sclerosis, hunter’s syndrome, brain cancer, and others. In 2021, parkinson’s disease segment held the largest share in the market, and epilepsy is expected to be the fastest growing segment during the forecast period. Similarly, Based on country the market is segmented into the US, Canada, and Mexico. In 2021, the US held the largest share in the market, and it is also expected to be the fastest growing country during the forecast period.
Teva Pharmaceutical Industries Ltd.; F. Hoffmann-La Roche Ltd.; Eli Lilly and Company; Bristol-Myers Squibb Company; Pfizer, Inc.; Johnson & Johnson Services, Inc.; Fabre-Kramer Pharmaceuticals, Inc.; and Bioasis Technologies, Inc. are among the leading companies in the North America blood brain barrier technologies market. The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market.
Contact Us
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com